section name header

Pronunciation

re-PAG-gli-nide

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: meglitinides

Indications

High Alert


Action

  • Stimulates the release of insulin from pancreatic beta cells by closing potassium channels, which results in the opening of calcium channels in beta cells. This is followed by release of insulin.
Therapeutic effects:
  • Lowering of blood glucose levels.

Pharmacokinetics

Absorption: Well absorbed (56%) following oral administration.

Distribution: Unknown.

Protein Binding: >98%.

Metabolism/Excretion: Mostly metabolized by the liver; metabolites are excreted primarily in feces.

Half-Life: 1 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
POwithin 30 min60–90 min<4 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Prandin

Canadian Brand Names

Gluconorm